These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study. Seeger N, Gutknecht S, Zschokke I, Fleischmann I, Roth N, Metzger J, Weber M, Breitenstein S, Grochola LF. JMIR Res Protoc; 2024 May 13; 13():e54042. PubMed ID: 38635586 [Abstract] [Full Text] [Related]
3. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants. Dimitrakopoulos C, Vrugt B, Flury R, Schraml P, Knippschild U, Wild P, Hoerstrup S, Henne-Bruns D, Wuerl P, Graf R, Breitenstein S, Bond G, Beerenwinkel N, Grochola LF. JAMA Surg; 2019 Jun 01; 154(6):e190484. PubMed ID: 30942874 [Abstract] [Full Text] [Related]
4. CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma. Stracquadanio G, Vrugt B, Flury R, Schraml P, Würl P, Müller TH, Knippschild U, Henne-Bruns D, Breitenstein S, Clavien PA, Graf R, Bond GL, Grochola LF. Clin Cancer Res; 2016 Dec 15; 22(24):6069-6077. PubMed ID: 27283965 [Abstract] [Full Text] [Related]
5. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Gentiluomo M, Puchalt García P, Galeotti AA, Talar-Wojnarowska R, Tjaden C, Tavano F, Strobel O, Kupcinskas J, Neoptolemos J, Hegyi P, Costello E, Pezzilli R, Sperti C, Lawlor RT, Capurso G, Szentesi A, Soucek P, Vodicka P, Lovecek M, Hackert T, Cavestro GM, Milanetto AC, Canzian F, Campa D. Carcinogenesis; 2019 Jun 10; 40(4):544-550. PubMed ID: 30629142 [Abstract] [Full Text] [Related]
6. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Schirmer MA, Lüske CM, Roppel S, Schaudinn A, Zimmer C, Pflüger R, Haubrock M, Rapp J, Güngör C, Bockhorn M, Hackert T, Hank T, Strobel O, Werner J, Izbicki JR, Johnsen SA, Gaedcke J, Brockmöller J, Ghadimi BM. J Natl Cancer Inst; 2016 May 10; 108(5):. PubMed ID: 26857392 [Abstract] [Full Text] [Related]
7. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. In Vivo; 2018 May 10; 32(6):1533-1540. PubMed ID: 30348713 [Abstract] [Full Text] [Related]
8. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Campa D, Rizzato C, Bauer AS, Werner J, Capurso G, Costello E, Talar-Wojnarowska R, Jamroziak K, Pezzilli R, Gazouli M, Khaw KT, Key TJ, Bambi F, Mohelnikova-Duchonova B, Heller A, Landi S, Vodickova L, Theodoropoulos G, Bugert P, Vodicka P, Hoheisel JD, Delle Fave G, Neoptolemos JP, Soucek P, Büchler MW, Giese N, Canzian F. Cancer Epidemiol Biomarkers Prev; 2013 Feb 10; 22(2):320-3. PubMed ID: 23250936 [Abstract] [Full Text] [Related]
9. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Campa D, Pastore M, Capurso G, Hackert T, Di Leo M, Izbicki JR, Khaw KT, Gioffreda D, Kupcinskas J, Pasquali C, Macinga P, Kaaks R, Stigliano S, Peeters PH, Key TJ, Talar-Wojnarowska R, Vodicka P, Valente R, Vashist YK, Salvia R, Papaconstantinou I, Shimizu Y, Valsuani C, Zambon CF, Gazouli M, Valantiene I, Niesen W, Mohelnikova-Duchonova B, Hara K, Soucek P, Malecka-Panas E, Bueno-de-Mesquita HBA, Johnson T, Brenner H, Tavano F, Fogar P, Ito H, Sperti C, Butterbach K, Latiano A, Andriulli A, Cavestro GM, Busch ORC, Dijk F, Greenhalf W, Matsuo K, Lombardo C, Strobel O, König AK, Cuk K, Strothmann H, Katzke V, Cantore M, Mambrini A, Oliverius M, Pezzilli R, Landi S, Canzian F. Int J Cancer; 2018 Jan 15; 142(2):290-296. PubMed ID: 28913878 [Abstract] [Full Text] [Related]
10. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Durko L, Wlodarski W, Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M, Hogendorf P, Strzelczyk J, Malecka-Panas E. Dis Markers; 2017 Jan 15; 2017():3276806. PubMed ID: 28659655 [Abstract] [Full Text] [Related]
11. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Hou YC, Chao YJ, Tung HL, Wang HC, Shan YS. Cancer; 2014 Sep 01; 120(17):2766-77. PubMed ID: 24839953 [Abstract] [Full Text] [Related]
12. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM. JAMA Oncol; 2018 Mar 08; 4(3):e173420. PubMed ID: 29098284 [Abstract] [Full Text] [Related]
13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM. World J Gastroenterol; 2015 Aug 21; 21(31):9348-57. PubMed ID: 26309360 [Abstract] [Full Text] [Related]
14. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. Sun B, Liu X, Gao Y, Li L, Dong Z. Br J Biomed Sci; 2016 Oct 21; 73(4):152-157. PubMed ID: 27922430 [Abstract] [Full Text] [Related]
15. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms. Zhou X, Liao X, Wang X, Huang K, Yang C, Yu T, Han C, Zhu G, Su H, Han Q, Chen Z, Huang J, Gong Y, Ruan G, Ye X, Peng T. Cancer Med; 2020 Feb 21; 9(3):859-871. PubMed ID: 31808619 [Abstract] [Full Text] [Related]
16. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients. Saha G, Singh R, Mandal A, Das S, Chattopadhyay E, Panja P, Roy P, DeSarkar N, Gulati S, Ghatak S, Ghosh S, Banerjee S, Roy B, Ghosh S, Chaudhuri D, Arora N, Biswas NK, Sikdar N. Mol Med; 2020 Jun 17; 26(1):59. PubMed ID: 32552660 [Abstract] [Full Text] [Related]
17. Low expression of TBX4 predicts poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Zong M, Meng M, Li L. Int J Mol Sci; 2011 Jun 17; 12(8):4953-63. PubMed ID: 21954337 [Abstract] [Full Text] [Related]
18. Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas. Fujiwara S, Saiki Y, Ishizawa K, Fukushige S, Yamanaka M, Sato M, Ishida M, Motoi F, Unno M, Horii A. Cancer Med; 2019 Apr 17; 8(4):1671-1678. PubMed ID: 30791220 [Abstract] [Full Text] [Related]
19. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. Ye HL, Li DD, Lin Q, Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM, Chen RW, Li ZH, Chen RF. World J Gastroenterol; 2015 Jun 07; 21(21):6621-30. PubMed ID: 26074700 [Abstract] [Full Text] [Related]
20. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma. Zhou C, Zhao Y, Yin Y, Hu Z, Atyah M, Chen W, Meng Z, Mao H, Zhou Q, Tang W, Wang P, Li Z, Weng J, Bruns C, Popp M, Popp F, Dong Q, Ren N. Int J Biol Sci; 2019 Jun 07; 15(11):2282-2295. PubMed ID: 31595147 [Abstract] [Full Text] [Related] Page: [Next] [New Search]